山矾科中原氏山矾复合体的叶形态特征及分类意义

该研究在形态学观察以及统计学分析的基础上,深入研究了山矾科中原氏山矾复合体的叶片形态学结构。结果表明:叶片质地在整个复合体中可分为革质、纸质2种类型,叶片大小变异幅度较大,除中原氏山矾(Symplocos kawakamii)、棱角山矾(S.tetragona)、蒙自山矾(S.henryi)均与其他种差异显著外,其余种均属于连续过度,叶片分形可以初步区分该复合体植物。该研究结果为中原氏山矾复合体的进一步研究提供了依据,对复合体的分类处理具有一定的分类学意义

Identification of blue light receptor phototropin (PHOT) interacting protein from Haematococcus pluvialis and physiological effect of its heterologous expression in tobacco

Photropin (PHOT) is a unique blue light receptor in plants and green algae.Identification of PHOT interacting proteins and their functions will lay a foundation for elucidating PHOT-mediated signaling pathways and physiological functions.In this study,the yeast two-hybridization (Y2H) was used to screen the candidate interacting proteins of HaePHOT from the cDNA library of Haematococcus pluvialis.A total of 23 positive clones were obtained,of which four clones were annotated as DnaJ.The expression correlation of HaePHOT and DnaJ in H.pluvialis showed a strong positive model basing on RNA-Seq data.Further analysis of the expression correlation between HaePHOT or DnaJ and astaxanthin synthetic genes showed that HaePHOT and DnaJ were positively correlated with LYCB,BKT,BCH and CYP97B,but negatively correlated with PSY,PDS,KAS and FAD,respectively.Transient expression assay in tobacco showed that there was no significant difference in chlorophyll a,chlorophyll b and carotenoids contents between wildtype tobacco and HaePHOT-overexpressing tobacco under normal light (white light).However,under blue light,the contents of those pigments were higher in the transient-expression plants than that in the wildtype tobacco.qRT-PCR analysis showed that the expression of genes encoding chlorophyll a oxygenase(CAO),protochlorophyllide oxidoreductase (POR),phytoene synthase (PSY),phytoene desaturase (PDS) and lycopene beta-cyclase (LYCB) were significantly increased under blue light irradiation in the transient-expression tobacco plants,which was consistent with the change pattern of chlorophylls and carotenoids contents.These findings provide a theoretical basis for further revealing the regulatory mechanisms mediated by HaePHOT and its interacting proteins

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements